Evidence brief
Afamelanotide
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
An FDA-approved implant exists for a rare-disease indication.
An approved implant that increases pain-free light exposure in adults with EPP. It is not a general tanning or cosmetic peptide.
- How strong is the evidence?
- Established
An official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone. - What evidence exists?
- Approved human outcomes
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed July 23, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Scenesse · Nle4-D-Phe7-alpha-MSH · melanocortin-1 agonist
Part of Melanocortin peptides
Words used here
- indication
- the approved or studied use and patient group
- peptide
- a short chain of amino acids
- outcome
- what the study measured
- agonist
- a substance that activates a receptor
- randomized
- assigned to study groups by chance
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- analog
- a changed version made to act like another substance
- molecule
- one specific chemical substance
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Randomized trials support pain-free light-exposure and quality-of-life outcomes in adults with EPP.
The approved implant's pharmacology and melanocortin-1 activity are characterized.
The label and postauthorization monitoring characterize known risks and skin-monitoring requirements.
High for authentic Scenesse; low for transfer to other melanocortin products.
02 · Identity
What it is
Afamelanotide is the active ingredient in the approved Scenesse implant. It is a changed version of a pigment-related body signal and acts mainly at the melanocortin-1 receptor.
Scientific group: Melanocortin-1 receptor agonist. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
Scenesse
2024 label- Formulation
- Controlled-release implant
- Route
- Subcutaneous implant administered by a trained professional
- Indication scope
- Increase pain-free light exposure in adults with erythropoietic protoporphyria and a history of phototoxic reactions.
- Scenesse
- Increase pain-free light exposure in adults with erythropoietic protoporphyria
04 · Research results
What the research shows
Randomized trials in erythropoietic protoporphyria, or EPP, reported more pain-free light exposure and improvements in disease-specific quality of life. FDA approved Scenesse for a corresponding adult population.
The approval does not establish general tanning, cosmetic anti-aging, athletic, or other disease benefits. It does not validate different melanocortin peptides.
Exact product
Scenesse is not the same as every tanning peptide or injection. Scenesse is a healthcare-professional-administered implant. It is not equivalent to tanning peptides, compounded injections, or other melanocortin analogues.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Afamelanotide increases pain-free light exposure in adults with EPP.”
The label and randomized trials support this defined rare-disease outcome.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Adults with a history of phototoxic reactions from erythropoietic protoporphyria. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Scenesse is an approved cosmetic tanning implant.”
Its approval is for pain-free light exposure in adults with EPP, not cosmetic tanning.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The current FDA-approved indication. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Afamelanotide evidence proves other tanning peptides are safe and effective.”
Different molecules and products require their own identity, quality, safety, and outcome evidence.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Other melanocortin analogues and unapproved products. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Afamelanotide
An FDA-approved implant exists for a rare-disease indication. Approved products identified: Scenesse.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
Randomized trials in erythropoietic protoporphyria, or EPP, reported more pain-free light exposure and improvements in disease-specific quality of life. FDA approved Scenesse for a corresponding adult population.
The approval does not establish general tanning, cosmetic anti-aging, athletic, or other disease benefits. It does not validate different melanocortin peptides.
07 · Safety
Safety limits for this record
The implant is administered by trained healthcare professionals and the label calls for skin monitoring. This guide provides no implant or cosmetic-use instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Initial brief based on the current Scenesse label, pivotal trials, and orphan-drug record.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.